Mersana Therapeutics Inc (MRSN) Stock Price, Quote & News

Company Profile

Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial. Its preclinical products portfolio includes XMT-2068 and XMT-2175. It has strategic research and dev...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 498 0020

Website: www.mersana.com

Address:

840 Memorial Drive, Cambridge, United States

Rony4AM Nov. 15 at 12:08 AM

$MRSN - As the pricing will go toward a fair 90 😁, I just can't wait to read all the dissing to come..

0 · Reply

Rony4AM Nov. 14 at 11:43 PM

$MRSN - Not my style to brag about thing, but there is time when you KNOW, a company is on the right track. A company that does the right thing for the right purpose. Mersana Therapeutics Inc, Thank you.

0 · Reply

himsssss Nov. 14 at 9:46 PM

$MRSN moving some $MTSR cash to fund this CVR buyout. atm its $2.77 for $31 dollars over the next 7 years if it pays out.

0 · Reply

WayneSmith Nov. 14 at 8:44 PM

$MRSN $TSLA The market rhythm is firmly in the hands of the bulls.

0 · Reply

WayneSmith Nov. 14 at 7:47 PM

$MRSN $CSIQ Bears are covering their shorts, further strengthening the upward trend.

1 · Reply

WayneSmith Nov. 14 at 7:39 PM

$BABA $MRSN The bulls launched a general offensive, and the bears' defense line collapsed.

0 · Reply

ewuzi01 Nov. 14 at 7:17 PM

$MRSN $PCSA

0 · Reply

gti10001 Nov. 14 at 3:17 PM

Mersana ($MRSN ) therapies skyrocket! Moderate Buy momentum – $12 target vs. $8.41. 43% biotech boost! Pipeline pros, dive in. #MRSN #BioBreakout

0 · Reply

AAUS1 Nov. 14 at 3:15 PM

$MRSN just wait for this to enter 3 digit . Patience

1 · Reply

Social_Idiot Nov. 14 at 2:31 PM

$MRSN gratz

0 · Reply

Mersana Therapeutics, Inc. (MRSN) M&A Call Transcript

Nov 13, 2025, 10:15 AM EST - 1 day ago

Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout

DAWN

Nov 13, 2025, 6:00 AM EST - 1 day ago

Day One Biopharmaceuticals to Acquire Mersana Therapeutics

Nov 10, 2025, 8:00 AM EST - 4 days ago

Mersana Therapeutics to Host Third Quarter 2025 Conference Call on November 14, 2025

Aug 13, 2025, 11:44 AM EDT - 3 months ago

Mersana Therapeutics, Inc. (MRSN) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 7:00 AM EDT - 3 months ago

Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results

Aug 6, 2025, 8:00 AM EDT - 3 months ago

Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025

Jul 24, 2025, 8:31 AM EDT - 4 months ago

Mersana Therapeutics Announces 1-for-25 Reverse Stock Split

Jun 2, 2025, 8:10 AM EDT - 5 months ago

Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting

May 20, 2025, 8:00 AM EDT - 6 months ago

Mersana Therapeutics to Present at Upcoming Investor Conferences

May 15, 2025, 10:06 AM EDT - 6 months ago

Mersana Therapeutics, Inc. (MRSN) Q1 2025 Earnings Call Transcript

May 15, 2025, 9:20 AM EDT - 6 months ago

CORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results

May 15, 2025, 7:00 AM EDT - 6 months ago

Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results

May 6, 2025, 7:00 AM EDT - 6 months ago

Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer

Apr 23, 2025, 10:12 AM EDT - 7 months ago

Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting

Apr 4, 2025, 4:05 PM EDT - 8 months ago

Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 1, 2025, 8:01 AM EDT - 8 months ago

Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress

Mar 3, 2025, 10:13 AM EST - 9 months ago

Mersana Therapeutics, Inc. (MRSN) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 7:01 AM EST - 9 months ago

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results

Feb 24, 2025, 4:01 PM EST - 9 months ago

Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025

Jan 30, 2025, 8:00 AM EST - 10 months ago

Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

Jan 10, 2025, 12:49 PM EST - 11 months ago

Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday?

Jan 10, 2025, 6:02 AM EST - 11 months ago

Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)

Jan 10, 2025, 6:00 AM EST - 11 months ago

Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer

Dec 19, 2024, 7:17 AM EST - 11 months ago

Mersana Therapeutics: We're About To Find Out If ADC Platform Is More Tolerable

Nov 13, 2024, 1:26 PM EST - 1 year ago

Mersana Therapeutics, Inc. (MRSN) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 7:00 AM EST - 1 year ago

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results

Nov 6, 2024, 8:00 AM EST - 1 year ago

Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024

Aug 13, 2024, 12:55 PM EDT - 1 year ago

Mersana Therapeutics, Inc. (MRSN) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 7:00 AM EDT - 1 year ago

Mersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Mersana Therapeutics to Host Second Quarter 2024 Conference Call on August 13, 2024

May 9, 2024, 2:09 PM EDT - 1 year ago

Mersana Therapeutics, Inc. (MRSN) Q1 2024 Earnings Call Transcript

May 9, 2024, 6:59 AM EDT - 1 year ago

Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results

May 3, 2024, 4:30 PM EDT - 1 year ago

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 2, 2024, 8:00 AM EDT - 1 year ago

Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024

Feb 28, 2024, 2:10 PM EST - 1 year ago

Mersana Therapeutics, Inc. (MRSN) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 7:00 AM EST - 1 year ago

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results

Feb 21, 2024, 8:00 AM EST - 1 year ago

Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024

Feb 1, 2024, 8:00 AM EST - 1 year ago

Mersana Therapeutics to Participate in Guggenheim's 6th Annual Biotechnology Conference

Jan 5, 2024, 8:01 AM EST - 2 years ago

Mersana Therapeutics Announces Business Updates, Expected 2024 Milestones and Upcoming Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 7, 2023, 1:34 PM EST - 2 years ago

Mersana Therapeutics, Inc. (MRSN) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 7:00 AM EST - 2 years ago

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results

Oct 31, 2023, 4:30 PM EDT - 2 years ago

Mersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023

Oct 31, 2023, 8:00 AM EDT - 2 years ago

Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056

Sep 6, 2023, 7:00 AM EDT - 2 years ago

Mersana Therapeutics Announces Changes in Leadership

Aug 8, 2023, 8:00 AM EDT - 2 years ago

Mersana Therapeutics Announces Second Quarter 2023 Financial Results

Jul 27, 2023, 7:06 AM EDT - 2 years ago

Mersana Therapeutics Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization

Rony4AM Nov. 15 at 12:08 AM

$MRSN - As the pricing will go toward a fair 90 😁, I just can't wait to read all the dissing to come..

0 · Reply

Rony4AM Nov. 14 at 11:43 PM

0 · Reply

himsssss Nov. 14 at 9:46 PM

$MRSN moving some $MTSR cash to fund this CVR buyout. atm its $2.77 for $31 dollars over the next 7 years if it pays out.

0 · Reply

WayneSmith Nov. 14 at 8:44 PM

$MRSN $TSLA The market rhythm is firmly in the hands of the bulls.

0 · Reply

WayneSmith Nov. 14 at 7:47 PM

$MRSN $CSIQ Bears are covering their shorts, further strengthening the upward trend.

1 · Reply

WayneSmith Nov. 14 at 7:39 PM

$BABA $MRSN The bulls launched a general offensive, and the bears' defense line collapsed.

0 · Reply

ewuzi01 Nov. 14 at 7:17 PM

$MRSN $PCSA

0 · Reply

gti10001 Nov. 14 at 3:17 PM

Mersana ($MRSN ) therapies skyrocket! Moderate Buy momentum – $12 target vs. $8.41. 43% biotech boost! Pipeline pros, dive in. #MRSN #BioBreakout

0 · Reply

AAUS1 Nov. 14 at 3:15 PM

$MRSN just wait for this to enter 3 digit . Patience

1 · Reply

Social_Idiot Nov. 14 at 2:31 PM

$MRSN gratz

0 · Reply

Bazzzigar Nov. 14 at 2:28 PM

$MRSN ABVE

0 · Reply

JarvisFlow Nov. 14 at 2:15 PM

Guggenheim has adjusted their stance on Mersana Therapeutics ( $MRSN ), setting the rating to Neutral.

0 · Reply

Rony4AM Nov. 14 at 2:12 PM

$MRSN - ❇️❇️❇️

0 · Reply

Rony4AM Nov. 14 at 2:09 PM

$MRSN -

0 · Reply

Rony4AM Nov. 14 at 1:36 PM

$MRSN -

0 · Reply

Rony4AM Nov. 14 at 1:31 PM

$MRSN - Well done !! To all the teams at Mersana Therapeutics Inc.

0 · Reply

d_risk Nov. 14 at 1:17 PM

$MRSN - Mersana Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors MRSN’s risk profile now centers on uncertainties and costs tied to its pending merger with Day One, new litigation and tax risks, expanded clinical and regulatory hurdles, supply chain threats from tariffs and China tensions, Nasdaq non-compliance, and a narrowed pipeline—while legacy risks around funding, restructuring, and internal controls persist. #Biotechnology #LitigationRisk #SupplyChainDisruption #RegulatoryRisk #MergersAndAcquisitions 🟢 Added 🟠 Removed https://d-risk.ai/MRSN/10-Q/2025-11-14

1 · Reply

Sarandon Nov. 14 at 12:31 PM

🟢 On Thursday, Day One Biopharmaceuticals acquired Mersana Therapeutics ($MRSN) in a deal worth up to $285 million... 💰 🟢 Today, Friday, Merk ($MERK.X) acquired Cidara Therapeutics ($CDTX) for $9.2 billion.💰 🙋 Will Coherus ($CHRS) be next? It's undervalued, cheap, and has plenty of cash...🤔

0 · Reply

TTCM Nov. 14 at 12:19 PM

$GRRR $HOOD $MRSN $SBET This was said about HOOD and AMC

0 · Reply

invbond Nov. 14 at 11:52 AM

$PCSA Top 5 Potential Acquirers – Rationale Table Note: Two 13G was filed over the past few days/week for 10.5m shares by institutions, $452.5M Intact deal + Why PCSA is a Buy-Out Candidate? 1. PCSA’s lead platform, its “Next Generation Cancer” (NGC) therapies which modify existing FDA-approved oncology drugs—presents an attractive, lower-risk oncology development path. 2. Its recent licensing deal structure (including equity upside via a 3.5% stake) adds non-dilutive value, making the company more enticing for acquisition. 3. The market sees large pharmaceutical and oncology players actively acquiring smaller companies to fill their pipelines; PCSA’s niche and clear clinical path give it strategic appeal. 4. A buyout premium offers liquidity and may compensate for public micro-cap volatility/dilution risks facing PCSA. $MRSN

0 · Reply

moonsdeveloper Nov. 14 at 11:50 AM

ARBB could be the next BIG retail SQUEEZE stock! $SBET $GRRR $MRSN $HOOD /

0 · Reply

Market Cap	136.90M
Revenue (ttm)	40.50M
Net Income (ttm)	-69.19M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-170.84%
Debt to Equity Ratio	-0.33

Volume	420,200
Avg Vol	122,054
Day's Range	N/A - N/A
Shares Out	4.99M
Stochastic %K	99%
Beta	0.92
Analysts	Sell
Price Target	$28.29